PMID- 36354719
OWN - NLM
STAT- MEDLINE
DCOM- 20221114
LR  - 20230112
IS  - 1718-7729 (Electronic)
IS  - 1198-0052 (Print)
IS  - 1198-0052 (Linking)
VI  - 29
IP  - 11
DP  - 2022 Nov 1
TI  - Racial/Ethnic Disparities in Patient Care Experiences among Prostate Cancer 
      Survivors: A SEER-CAHPS Study.
PG  - 8357-8373
LID - 10.3390/curroncol29110659 [doi]
AB  - PURPOSE: To evaluate racial/ethnic disparities in patient care experiences (PCEs) 
      among prostate cancer (PCa) survivors. METHODS: This retrospective study used 
      2007-2015 National Cancer Institute Surveillance, Epidemiology and End Results 
      registry data linked to Consumer Assessment of Healthcare Providers and Systems 
      surveys. First survey >/= 6 months post-PCa diagnosis was analyzed. We performed 
      multivariable linear regression, adjusting for demographic and clinical 
      covariates, to evaluate the association of race/ethnicity (non-Hispanic Whites 
      (NHWs), non-Hispanic Black (NHBs), Hispanic, non-Hispanic Asian (NHAs), and other 
      races) with PCE composite measures: getting needed care, doctor communication, 
      getting care quickly, getting needed prescription drugs (Rx), and customer 
      service. RESULTS: Among 7319 PCa survivors, compared to NHWs, Hispanics, NHBs and 
      NHAs reported lower scores for getting care quickly (ss = -3.69; p = 0.002, ss = 
      -2.44; p = 0.021, and ss = -6.44; p < 0.001, respectively); Hispanics scored worse 
      on getting needed care (ss = -2.16; p = 0.042) and getting needed Rx (ss = -2.93; p 
      = 0.009), and NHAs scored worse on customer service (ss = -7.60; p = 0.003), and 
      getting needed Rx (ss = -3.08; p = 0.020). However, NHBs scored better than NHWs 
      on doctor communication (ss = 1.95, p = 0.006). No statistically significant 
      differences were found between other races and NHWs. CONCLUSIONS: Comparing to 
      NHWs, Hispanics and NHAs reported worse experiences on several PCE composite 
      measures, while NHBs reported worse scores on one but better scores on another 
      PCE composite measure. Further research is needed to understand the reasons 
      behind these disparities and their influence on healthcare utilization and health 
      outcomes among PCa survivors.
FAU - Pandit, Ambrish A
AU  - Pandit AA
AUID- ORCID: 0000-0003-3049-7516
AD  - Department of Pharmacy Practice, University of Arkansas for Medical Sciences, 
      Little Rock, AR 72211, USA.
FAU - Gressler, Laura E
AU  - Gressler LE
AUID- ORCID: 0000-0003-2042-2174
AD  - Department of Pharmacy Practice, University of Arkansas for Medical Sciences, 
      Little Rock, AR 72211, USA.
FAU - Halpern, Michael T
AU  - Halpern MT
AUID- ORCID: 0000-0001-8514-6313
AD  - Division of Cancer Control and Population Sciences, National Cancer Institute, 
      Bethesda, MD 20892, USA.
FAU - Kamel, Mohamed
AU  - Kamel M
AD  - College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
AD  - Department of Urology, Ain Shams University, Cairo 11566, Egypt.
FAU - Payakachat, Nalin
AU  - Payakachat N
AUID- ORCID: 0000-0002-9526-5356
AD  - Department of Pharmacy Practice, University of Arkansas for Medical Sciences, 
      Little Rock, AR 72211, USA.
FAU - Li, Chenghui
AU  - Li C
AD  - Department of Pharmacy Practice, University of Arkansas for Medical Sciences, 
      Little Rock, AR 72211, USA.
LA  - eng
GR  - UL1 TR003107-02S2/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20221101
PL  - Switzerland
TA  - Curr Oncol
JT  - Current oncology (Toronto, Ont.)
JID - 9502503
SB  - IM
MH  - Male
MH  - Humans
MH  - Ethnicity
MH  - *Cancer Survivors
MH  - Prostate
MH  - Retrospective Studies
MH  - Patient Care
MH  - *Prostatic Neoplasms/therapy
PMC - PMC9689524
OTO - NOTNLM
OT  - CAHPS
OT  - SEER
OT  - disparity
OT  - patient care experiences
OT  - prostate cancer
COIS- MH is an editor serving in personal capacity on the board of Current Oncology. 
      Other authors have no conflict of interest to declare. CL received research 
      funding for unrelated projects sponsored by University of Utah/AstraZeneca.
EDAT- 2022/11/11 06:00
MHDA- 2022/11/15 06:00
PMCR- 2022/11/01
CRDT- 2022/11/10 09:44
PHST- 2022/09/09 00:00 [received]
PHST- 2022/10/24 00:00 [revised]
PHST- 2022/10/29 00:00 [accepted]
PHST- 2022/11/10 09:44 [entrez]
PHST- 2022/11/11 06:00 [pubmed]
PHST- 2022/11/15 06:00 [medline]
PHST- 2022/11/01 00:00 [pmc-release]
AID - curroncol29110659 [pii]
AID - curroncol-29-00659 [pii]
AID - 10.3390/curroncol29110659 [doi]
PST - epublish
SO  - Curr Oncol. 2022 Nov 1;29(11):8357-8373. doi: 10.3390/curroncol29110659.